HomeCompareIDYLF vs ABBV

IDYLF vs ABBV: Dividend Comparison 2026

IDYLF yields 8510.64% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IDYLF wins by $11275090002034350.00M in total portfolio value
10 years
IDYLF
IDYLF
● Live price
8510.64%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11275090002034350.00M
Annual income
$11,020,364,972,549,812,000,000.00
Full IDYLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — IDYLF vs ABBV

📍 IDYLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIDYLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IDYLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IDYLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IDYLF
Annual income on $10K today (after 15% tax)
$723,404.26/yr
After 10yr DRIP, annual income (after tax)
$9,367,310,226,667,340,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, IDYLF beats the other by $9,367,310,226,667,340,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IDYLF + ABBV for your $10,000?

IDYLF: 50%ABBV: 50%
100% ABBV50/50100% IDYLF
Portfolio after 10yr
$5637545001017175.00M
Annual income
$5,510,182,486,274,906,000,000.00/yr
Blended yield
97.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

IDYLF
No analyst data
Altman Z
-2215.1
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IDYLF buys
0
ABBV buys
0
No recent congressional trades found for IDYLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIDYLFABBV
Forward yield8510.64%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$11275090002034350.00M$102.3K
Annual income after 10y$11,020,364,972,549,812,000,000.00$24,771.77
Total dividends collected$11258090234499652.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IDYLF vs ABBV ($10,000, DRIP)

YearIDYLF PortfolioIDYLF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$861,764$851,063.83$11,550$430.00+$850.2KIDYLF
2$69,465,641$68,543,553.77$13,472$627.96+$69.45MIDYLF
3$5,238,071,316$5,163,743,080.34$15,906$926.08+$5238.06MIDYLF
4$369,504,863,499$363,900,127,190.11$19,071$1,382.55+$369504.84MIDYLF
5$24,386,305,624,480$23,990,935,420,536.29$23,302$2,095.81+$24386305.60MIDYLF
6$1,505,846,443,096,396$1,479,753,096,078,202.50$29,150$3,237.93+$1505846443.07MIDYLF
7$87,007,772,087,222,740$85,396,516,393,109,600.00$37,536$5,121.41+$87007772087.19MIDYLF
8$4,704,508,325,433,012,000$4,611,410,009,299,683,300.00$50,079$8,338.38+$4704508325432.96MIDYLF
9$238,060,775,219,195,000,000$233,026,951,310,981,700,000.00$69,753$14,065.80+$238060775219194.91MIDYLF
10$11,275,090,002,034,350,000,000$11,020,364,972,549,812,000,000.00$102,337$24,771.77+$11275090002034350.00MIDYLF

IDYLF vs ABBV: Complete Analysis 2026

IDYLFStock

Imaging Dynamics Company Ltd., a medical technology company, provides digital radiography equipment in the Americas and internationally. The company offers imaging detectors; and flat panel detectors under Aquarius 8600 and VetnovaXion names. It also provides Magellan, a medical image processing software; and Sirius, a veterinary image processing software. In addition, the company provides 1600 Plus X-Series, a DR solution with a floor mounted U-arm multi-axis positioning device that includes X-ray tube, collimator, and generator; and veterinary DR systems. It offers products through dealers, distributors, and original equipment manufacturer partners. The company was formerly known as Imaging Dynamics Corporation and changed its name to Imaging Dynamics Company Ltd. in October 2001. Imaging Dynamics Company Ltd. was incorporated in 1995 and is headquartered in Toronto, Canada.

Full IDYLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this IDYLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IDYLF vs SCHDIDYLF vs JEPIIDYLF vs OIDYLF vs KOIDYLF vs MAINIDYLF vs JNJIDYLF vs MRKIDYLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.